Login / Signup

A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.

Jiayi HuangRekha ChaudharyAdam L CohenKaren FinkSamuel GoldlustJohn BoockvarPrakash ChinnaiyanLeping WanStephen MarcusJian L Campian
Published in: Journal of neuro-oncology (2019)
Addition of DSF/Cu to TMZ for TMZ-resistant IDH-wild type GBM appears well tolerated but has limited activity for unselected population.
Keyphrases
  • wild type
  • phase ii study
  • open label
  • locally advanced
  • newly diagnosed
  • cross sectional
  • squamous cell carcinoma
  • randomized controlled trial
  • radiation therapy
  • aqueous solution